IDEAYA Biosciences (IDYA) Change in Receivables (2021 - 2024)
IDEAYA Biosciences (IDYA) posted Change in Receivables of -$2000.0 for Q4 2024, down 110.53% sequentially from $19000.0 in Q3 2024, and up 99.97% YoY from -$1000.1 in Q1 2024.
IDEAYA Biosciences (IDYA) Change in Receivables (2021 - 2024) Analysis & Trends
IDEAYA Biosciences has reported Change in Receivables for 4 years, with the latest figure at -$2000.0 in Q4 2024.
- Quarterly Change in Receivables rose 99.97% year-over-year to -$2000.0 in Q4 2024, while the trailing twelve-month figure through Sep 2024 was -$6.7 million (down 305.38% YoY) and the FY2023 annual result came in at -$193000.0, up 78.36% from the prior year.
- Change in Receivables eased to -$2000.0 in Q4 2024 per IDYA's latest filing, from $19000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $6.5 million in Q3 2023 and troughed at -$6.7 million in Q4 2023.
- A 4-year average of -$116187.5 and a median of -$8500.0 in 2024 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 1129.64% in 2022, down 3909.41% in 2022.
- Over 4 years, Change in Receivables stood at $85000.0 in 2021, then slumped by 3909.41% to -$3.2 million in 2022, then sank by 106.45% to -$6.7 million in 2023, then soared by 99.97% to -$2000.0 in 2024.
- According to Business Quant data, Change in Receivables over the past three periods registered -$2000.0, $19000.0, and -$14000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | IDEAYA Biosciences | 3.50 Bn | 2.67 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2,000.00 |
| Dec 31, 2024 | -2,000.00 |
| Sep 30, 2024 | 19,000.00 |
| Sep 30, 2024 | 19,000.00 |
| Jun 30, 2024 | -14,000.00 |
| Jun 30, 2024 | -14,000.00 |
| Mar 31, 2024 | -3,000.00 |
| Mar 31, 2024 | -3,000.00 |
| Dec 31, 2023 | -6.69 Mn |
| Dec 31, 2023 | -6.69 Mn |
| Sep 30, 2023 | 6.54 Mn |
| Sep 30, 2023 | 6.54 Mn |
| Jun 30, 2023 | -308,000.00 |
| Jun 30, 2023 | -308,000.00 |
| Mar 31, 2023 | 257,000.00 |
| Mar 31, 2023 | 257,000.00 |
| Dec 31, 2022 | -3.24 Mn |
| Dec 31, 2022 | -3.24 Mn |
| Sep 30, 2022 | 3.16 Mn |
| Sep 30, 2022 | 3.16 Mn |